A shares: jiuan medical and other six companies important announcement
A shares: Jiuan Medical and other six companies important announcement 1, Jiuan Medical:The subsidiary has delivered a total of 105 million units of iHealth kit products to the contract counterparty. The Us subsidiary of the Company has delivered a total of 105 million units of iHealth kit products to the contract counterparty.ACC paid a total of 108 million US dollars to the COMPANY’s US subsidiary for the kit products of 21.168 million people on February 7, 2022 local time. The above payment has been received, about 687 million RMB yuan.2, China resources: lump-sum anti-infection business in 2022 is expected to achieve double-digit growth CRC san-jiu disclosure of investor relations activities record announcement, anti-infection business affected by the policy a few years ago is bigger, anti-infection business impact has been largely last year fell to the bottom, at the same time in the past few years anti-infection business in a CMO business development, also help anti-infection business remained stable.In 2022, the anti-infection business is expected to achieve double-digit growth driven by the basic adjustment of product mix and new products.3. Baoxin Technology: Chen Dong has passively reduced his stake by 1%. Baoxin Technology announced that the shareholder Chen Dong has passively reduced his stake by 5.54 million shares, or 1%, due to the fact that some of the shares pledged to Capital Securities Co., Ltd. were liquidated due to the triggering of the default clause of the agreement.4, *ST HNA: actual controller Fang Wei plans to increase the holding of 50 million shares to 100 million shares *ST HNA announced that the actual controller Fang Wei plans to increase the holding of the company’s shares through the Shanghai Stock Exchange centralized bidding trading system within 6 months from February 10.The proposed increase in the number of 50 million to 100 million shares (approximately 0.15% to 0.30% of the company’s shares).There is no price range for this increase, and the increase will be carried out according to the stock price fluctuation of the company and the overall trend of the capital market.5, Shanghai Shanghai industrial performance express: 2021 net profit rose 35.32% to 164 million yuan Shanghai issued the 2021 annual performance express, to achieve total operating revenue of 1.308 billion yuan, a year-on-year growth of 20.48%;Net profit attributable to shareholders of listed companies was 164 million yuan, up 35.32% year on year;Basic earnings per share of 0.52 yuan.6. The company has announced the completion of the first patient administration of Teriprizumab (Teriprizumab) JUPITER 15 trial.JS001) in combination with standard chemotherapy as adjunctive therapy after radical resection of gastric or esophagogastric junction adenocarcinoma (the “Jupiter-15 study”, NCT05180734) has completed its first patient administration.